Skip to main content

Hemophagocytic Lymphohistiocytoses

4
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

GAMIFANTApproved
emapalumab-lzsg
Unknown Company
Interferon gamma Blocker [EPC]injection2018
983K Part D

Competitive Landscape

4 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
DexamethasonePhase 41 trial
Active Trials
NCT05491304Unknown400Est. Dec 2025
Light Chain Bioscience
Light Chain BioscienceSwitzerland - Geneva
1 program
1
Emapalumab-LzsgPhase 2/31 trial
Active Trials
NCT03985423Terminated7Est. Jun 2021
Incyte
IncyteDE - Wilmington
1 program
1
RuxolitinibPhase 2Small Molecule1 trial
Active Trials
NCT06160791Recruiting36Est. Nov 2029
Swedish Orphan Biovitrum
2 programs
Blood Draws Data CollectionN/A1 trial
Emapalumab-LzsgPHASE_2_3
Active Trials
NCT06047210Completed14Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UNION therapeuticsDexamethasone
Light Chain BioscienceEmapalumab-Lzsg
IncyteRuxolitinib
Swedish Orphan BiovitrumBlood Draws Data Collection

Clinical Trials (4)

Total enrollment: 457 patients across 4 trials

NCT05491304UNION therapeuticsDexamethasone

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Start: Sep 2022Est. completion: Dec 2025400 patients
Phase 4Unknown
NCT03985423Light Chain BioscienceEmapalumab-Lzsg

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

Start: Jun 2020Est. completion: Jun 20217 patients
Phase 2/3Terminated
NCT06160791IncyteRuxolitinib

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Start: Oct 2024Est. completion: Nov 202936 patients
Phase 2Recruiting
NCT06047210Swedish Orphan BiovitrumBlood Draws Data Collection

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

Start: Dec 2016Est. completion: Oct 201914 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 457 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.